ECT and tardive dyskinesia.
ABSTRACT Three cases of elderly depressed patients with symptoms of tardive dyskinesia (TD) subsequently treated with electroconvulsive therapy (ECT) are presented. These cases are discussed in relation to several cases reported in the literature of ECT and TD. The possibility of improvement in symptoms of TD in certain patients is discussed.
- SourceAvailable from: Sunao Kaneko[Show abstract] [Hide abstract]
ABSTRACT: Tardive dystonia and dyskinesia are potentially irreversible neurological syndromes. Successful electroconvulsive treatment (ECT) has been reported by multiple sources; however, the existing retrospective reviews and open prospective trials provide little information on the response rate.Neuropsychiatric Disease and Treatment 01/2014; 10:1209-12. · 2.00 Impact Factor
- Journal of Neurology 10/2012; · 3.58 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.The World Journal of Biological Psychiatry 12/2012; · 3.57 Impact Factor